Latest News

Janssen reports positive results in Phase III combination trial to treat HIV

Janssen Sciences Ireland (Janssen) has reported positive results in the first of the two Phase III studies that evaluate the safety and efficacy of switching virologically suppressed patients...

Janssen reports positive results in Phase III combination trial to treat HIV

Soligenix reports positive long-term follow-up results from its Phase 2 clinical trial of SGX942

Soligenix reports positive long-term follow-up results from its Phase 2 clinical trial of SGX942

M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent

Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan,...

M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent

Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune

Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in...

Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune

M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici

Allergen has acquired Chase Pharmaceuticals Corporation from New Rhein Healthcare Investors for a purchase consideration of...

M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici

Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics

Rosetta Genomics and Sheba Medical Centre have entered a research agreement to develop and evaluate the efficacy of microRNA biomarkers to analyse the response of the drug nivolumab in lung...

Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease

Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn’s disease...

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn’s disease

Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study

Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210. ...

Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study

M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry

Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis...

M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry

Deals this week: Pfizer, Peakdale Molecular, Selexis

Pfizer and National Cancer Institute have entered a co-operative research and development (R&D) agreement to develop novel immunotherapy candidates targeting multiple...

Deals this week: Pfizer, Peakdale Molecular, Selexis

M&As this week: Sichuan Kelun Pharma, CiToxLAB

Sichuan Kelun Pharma has announced its intention to acquire stakes in two pharmaceutical companies, one based in Guangxi and another in...

M&As this week: Sichuan Kelun Pharma, CiToxLAB

Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics

GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy...

Deals this week: GeoVax Labs, Yisheng Biopharma, Oryzon Genomics

M&As this week: Signal Genetics, Celldex Therapeutics

US-based molecular diagnostic company Signal Genetics is set to merge with clinical-stage biopharmaceutical company miRagen Therapeutics, with the boards of directors of both companies...

M&As this week: Signal Genetics, Celldex Therapeutics

Deals this week: miRagen Therapeutics, Zhongyuan Union Cell, Health Advance

US-based biopharmaceutical company miRagen Therapeutics plans to raise $40m through private placement of its common stock shares with the help of placement agent Wedbush...

Deals this week: miRagen Therapeutics, Zhongyuan Union Cell, Health Advance

M&As this week: I’rom Group, Walgreens Boots Alliance

I’rom Group Co plans to acquire a 61% stake in CMAX from IDT Australia for a purchase consideration of A$10m...

M&As this week: I’rom Group, Walgreens Boots Alliance

Deals this week: Kerecis, PharmaJet, Fimbrion Therapeutics

Kerecis and the US Department of Defence have entered an agreement to develop fish skin burn...

Deals this week: Kerecis, PharmaJet, Fimbrion Therapeutics

Report: Penetrating crowded heart failure market could prove difficult for Omecamtiv Mecarbil

Cytokinetics’ new heart failure drug, Omecamtiv Mecarbil (OM), will have to target patient subgroups in order to succeed in the crowded heart failure market, says GlobalData in its recent...

Report: Penetrating crowded heart failure market could prove difficult for Omecamtiv Mecarbil

Deals this week: ATCC, Sirenas, Nektar Therapeutics

ATCC and BioAgilytix have entered a partnership to develop assay systems, which can be used for testing drug potency, stability testing and other...

Deals this week: ATCC, Sirenas, Nektar Therapeutics

M&As this week: Chengdu Kanghong Pharmaceutical, Cachet Pharmaceutical, Antegrin Therapeutics

Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group has announced its intention to acquire the remaining 7% stake in a pharmaceutical unit based in Chengdu,...

M&As this week: Chengdu Kanghong Pharmaceutical, Cachet Pharmaceutical, Antegrin Therapeutics

Deals this week: Nordic Nanovector ASA, Charles River Laboratories International, Transgene SA

Nordic Nanovector ASA and LegoChem Biosciences have entered an agreement to include CD37-targeting antibody drug conjugates to non-radionuclide cancer...

Deals this week: Nordic Nanovector ASA, Charles River Laboratories International, Transgene SA

M&As this week: RXi Pharmaceuticals, TFS International, Danaher Corporation

RXi Pharmaceuticals plans to expand its product pipeline and enter the immuno-oncology market by acquiring all the outstanding shares of cancer immunotherapies developer...

M&As this week: RXi Pharmaceuticals, TFS International, Danaher Corporation
cachename:Newscachekey:rd-137342983_-144940029_rd-1665407042_1857678299_rd-488908060_1460672566_ap1460672566_1857678299_-1943215794